News on qPCR, digital PCR, amplification, point-of-care testing platforms in genetics, genomics, and molecular diagnostics.
The firm’s two-step multiplexed-tandem PCR tool identifies low concentrations of multiple STI pathogens in samples with high concentrations of other pathogens in three hours.
The portable, battery-operated system will be an interim solution for decentralized testing in places where power may be unreliable.
The company, which merged with Transgenomic in 2016, attributed the revenue increase to strong demand for its pathology services.
Formerly known as SlipChip Corp, the firm has recently won nearly $10 million in funding to hone its approaches to sepsis and CT/NG testing.
The firm aims to commercialize its platform for infectious disease testing in the US by mid to late 2019, and continues to explore additional financing options.
